intranasal delivery is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid from research suppliers |
| Solubility | Freely soluble in water | Also dissolves in aqueous buffers; solutions are used fresh |
| Typical storage temperature | -20 °C for lyophilized powder | Short-term transport at 2-8 °C is common |
| Common analytical method | Reverse-phase HPLC | Paired with mass spectrometry for identity confirmation |
| Common synonyms | ACTH(4-10) analogue; MEHFPGP | N-terminal methionine retained in the chain |
Published studies are dominated by animal models of stroke, ischemia, and cognitive impairment, with a smaller number of human trials conducted in Russia. Many of the human reports are small, single-center, and published in Russian-language journals, which limits independent scrutiny. Outcome measures vary between studies and often rely on clinician-rated scales rather than objective biomarkers. Systematic reviews have noted the methodological weaknesses and called for larger, preregistered trials before firm conclusions can be drawn.
Claims about enhanced focus, memory, or mood in healthy people rest mostly on anecdotal reports and community discussion rather than on controlled data. It remains unclear whether any cognitive benefit observed in patients recovering from brain injury would extend to uninjured users. Dose-response relationships, long-term safety, and interactions with other drugs are not well characterized in the peer-reviewed literature. Questions about optimal route of administration and treatment duration likewise remain open.
Semax binds to melanocortin receptors and is thought to influence neuronal survival and plasticity rather than to act through the adrenal axis. Laboratory work has shown increased expression of brain-derived neurotrophic factor and nerve growth factor in treated tissue. Changes in c-Fos, a marker of neuronal activation, have also been reported. Because the peptide is rapidly degraded by peptidases, its effects are generally attributed to downstream signaling cascades rather than to sustained receptor occupancy.
=== Cancer === After inflammation, restoration of normal tissue integrity and function is preserved by feedback interactions between diverse cell types mediated by adhesion molecules and secreted cytokines. Disruption of normal feedback mechanisms in cancer threatens tissue integrity and enables a malignant tumor to escape the immune system. An example of the importance of the wound healing response within tumors is illustrated in work by Howard Chang and colleagues at Stanford University studying breast cancers.
In total, 32 radioisotopes have been characterised, which range in mass number from 207 to 238. After 232Th, the most stable of them (with respective half-lives) are 230Th (75,400 years), 229Th (7,916 years), 228Th (1.91 years), 234Th (24.11 days), and 227Th (18.693 days). All of these isotopes occur in nature as trace radioisotopes due to their presence in the decay chains of 232Th, 235U, 238U, and 237Np: the last of these is long extinct in nature due to its short half-life (2.14 million years), but is continually produced in minute traces from neutron capture in uranium ores. 233Th (half-life 22 minutes) occurs naturally as the result of neutron activation of natural 232Th. In deep seawaters the isotope 230Th constitutes up to 0.02% of total thorium. This is because its parent uranium is generally soluble in the ocean, but 232Th is nearly insoluble and is precipitated; thus the isotopes continually produced from uranium is relatively enriched. For this reason International Union of Pure and Applied Chemistry (IUPAC) reclassified thorium as a binuclidic element in 2013; it had formerly been considered a mononuclidic element. Thorium has a nuclear isomer, 229mTh, having the lowest known excitation energy of any isomer, measured to be 7.6±0.5 eV. This is so low that when it undergoes isomeric transition, the emitted gamma radiation is in the ultraviolet range. The nuclear transition from 229Th to 229mTh is being investigated for a nuclear clock.
Tofogliflozin (INN, USAN, codenamed CSG452) is a drug developed for the treatment of diabetes mellitus type 2 and was originally co-developed by Chugai Pharma in collaboration with Kowa and Sanofi. It is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. As of 2014, tofogliflozin was approved for use in Japan and is marketed under the brand names Apleway and Deberza. It has not been approved for use outside of Japan.
Sources: en.wikipedia.org
Another area of his research has been the investigation of the fatty acid transport system in human placenta and its roles in the placental preferential transfer of critically important nutrients such as docosahexaenoic acid, 22:6n-3 (DHA) and arachidonic acid, 20:4n-6 (ARA) from the mother to the fetus. He demonstrated the presence of several plasma membrane-located transport/binding proteins, such as fatty acid translocase (FAT/CD36), plasma membrane fatty acid binding protein (FABPpm), fatty acid transport protein (FATP), and intracellular FABPs, in the human placenta. He identified that the placental-specific FABPpm is mainly responsible for the preferential placental transport of DHA and ARA from the mother to support fetal brain growth during the third trimester.
As can be seen in the formula, the variation of K must be isosteric, that is, at constant coverage. If we start from the BET isotherm and assume that the entropy change is the same for liquefaction and adsorption, we obtain
The discovery of an orally inactive peptide from the skin of poisonous frogs established the important role of angiotensin converting enzyme (ACE) inhibitors in regulating blood pressure. This led to the development of captopril, the first ACE inhibitor. When the adverse effects of captopril became apparent new derivates were designed. Then after the discovery of two active sites of ACE: N-domain and C-domain, the development of domain-specific ACE inhibitors began.
== Integration & Processing == The major tool of the chromatographic software is peaks "integration". A series of articles describes it: Peak Integration Part 1, Peak Integration Part 2, Peak Integration Part 3. The parameters inside the chromatography software which affect the integration are called the Integration events. Peak integration in any chromatographic software refers to the process of quantifying the areas under the peak's curve in the chromatogram. The area under the peak is proportional to the amount of that particular component in the sample. Here are the basics of peak integration in a chromatographic system:
Sources: en.wikipedia.org
Heroin is generally a preferred product for smuggling and distribution—over unrefined opium due to the cost-effectiveness and increased efficacy of heroin. Because of the high cost per volume, heroin is easily smuggled. A US quarter-sized (2.5 cm) cylindrical vial can contain hundreds of doses. From the 1930s to the early 1970s, the so-called French Connection supplied the majority of US demand. Allegedly, during the Vietnam War, drug lords such as Ike Atkinson used to smuggle hundreds of kilograms of heroin to the US in coffins of dead American soldiers (see Cadaver Connection). Since that time it has become more difficult for drugs to be imported into the US than it had been in previous decades, but that does not stop the heroin smugglers from getting their product across US borders. Purity levels vary greatly by region with Northeastern cities having the most pure heroin in the United States. On 17 October 2018 police in Genoa, Italy discovered 270 kg (600 lb) of heroin hidden in a ship coming from the Iranian southern port of Bandar Abbas. The ship had already passed and stopped at Hamburg in Germany and Valencia in Spain. Penalties for smuggling heroin or morphine are often harsh in most countries. Some countries will readily hand down a death sentence (e.g. Singapore) or life in prison for the illegal smuggling of heroin or morphine, which are both internationally Schedule I drugs under the Single Convention on Narcotic Drugs. In May 2021, Romania seized 1.4 tonnes of heroin at Constanța port of a shipment from Iran that was headed for Western Europe.
== DNA assembly == DNA printing can thus be used to produce DNA parts, which are defined as sequences of DNA that encode a specific biological function (for example, promoters, transcription regulatory sequences or open reading frames). However, because oligonucleotide synthesis typically cannot accurately produce oligonucleotides sequences longer than a few hundred base pairs, DNA assembly methods have to be employed to assemble these parts together to create functional genes, multi-gene circuits or even entire synthetic chromosomes or genomes. Some DNA assembly techniques only define protocols for joining DNA parts, while other techniques also define the rules for the format of DNA parts that are compatible with them. These processes can be scaled up to enable the assembly of entire chromosomes or genomes. In recent years, there has been proliferation in the number of different DNA assembly standards with 14 different assembly standards developed as of 2015, each with their pros and cons. Overall, the development of DNA assembly standards has greatly facilitated the workflow of synthetic biology, aided the exchange of material between research groups and also allowed for the creation of modular and reusable DNA parts. The various DNA assembly methods can be classified into three main categories – endonuclease-mediated assembly, site-specific recombination, and long-overlap-based assembly. Each group of methods has its distinct characteristics and their own advantages and limitations.
COL1A1/2-related osteogenesis imperfecta is inherited in an autosomal dominant manner. The proportion of cases caused by a De novo COL1A1 or COL1A2 mutations are the cause of osteogenesis imperfecta in the vast majority of perinatally lethal osteogenesis imperfecta, and progressively deforming osteogenesis imperfecta. In classic non-deforming osteogenesis imperfecta with blue sclerae or common variable osteogenesis imperfecta with normal sclerae, nearly 60% of cases are de novo. COL1A1/2-related osteogenesis imperfecta is identified by repeated fractures with trivial trauma, defective dentinogenesis imperfecta (DI), and hearing loss. The clinical features of COL1A1/2-related osteogenesis imperfecta can be highly variable ranging from severe and lethal perinatal fractures to individuals with minimal tendency to repeated fractures and skeletal deformities and with a normal stature and life span. In between the clinical spectrum may include individuals with various degrees of disabling skeletal deformities and short stature. The radiographic findings of osteogenesis imperfecta include; long bone deformations such as bowing of the tibias and femurs, pencil-like deformity and tapering of bones, cortical thinning and rarefaction, pathologic fractures at various degrees of healing, bone shortening and vertebral wedging. Accordingly, COL1A1/2-related osteogenesis imperfecta has been classified into four sub-types (I, II, III, and IV) built upon the diversity of the radioclinical features.
Sources: en.wikipedia.org
It consists mainly of animal experiments and small clinical reports, with much of the clinical material published in Russian-language journals. Large independent trials are scarce. Separating reliable effects from chance findings is consequently difficult.
A fraction of an intranasal dose is thought to reach the central nervous system, and this route is favoured partly for that reason. The proportion is not well characterized. Direct measurement in humans remains difficult with current methods.
Raised BDNF and NGF expression has been reported across several animal studies, which makes the signal fairly consistent. Whether the same change occurs in humans at usable doses is not established. It is best treated as a working hypothesis rather than a confirmed clinical mechanism.
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.